Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon
- PMID: 27129579
- DOI: 10.1158/1078-0432.CCR-16-0582
Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon
Abstract
Cetuximab-platinum chemotherapy is used for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC); however, a minority of patients benefit. Gene expression profiling (GEP) of HNSCCs with prolonged responses to cetuximab-chemotherapy demonstrate basal subtype traits including signatures of EGFR signaling and hypoxic differentiation. GEP of short-response patients show RAS activation. Clin Cancer Res; 22(15); 3710-2. ©2016 AACRSee related article by Bossi et al., p. 3961.
©2016 American Association for Cancer Research.
Comment on
-
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.Clin Cancer Res. 2016 Aug 1;22(15):3961-70. doi: 10.1158/1078-0432.CCR-15-2547. Epub 2016 Feb 26. Clin Cancer Res. 2016. PMID: 26920888
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
